← Retour au Screener

Sector: Santé
Open in Terminal → PSNLLive chart · Key metrics · News · Smart money

Personalis

PSNL Small Cap

Healthcare · Diagnostics & Research

Mis à jour: Aug 2, 2026, 22:14 UTC

10,98 €
+3.09% aujourd'hui
52W: 3,33 € – 14,21 €
52W Low: 3,33 € Position: 70.3% 52W High: 14,21 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
20.95x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
1,2 Md €
Capitalisation boursière
Croissance du CA
-24.9%
Croissance du CA sur un an
Marge bénéficiaire
-148.11%
Marge nette
ROE
-41.35%
Rentabilité des capitaux propres
Beta
2.24
Sensibilité au marché
Positions vendeuses
16.74%
% du flottant vendu à découvert
Volume moyen
3,896,585
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Acheter
4 analysts
Avg. Price Target
12,03 €
+9.6% upside
Target Range
8,67 € – 14,09 €

About the Company

Sector: Healthcare Industry: Diagnostics & Research Country: United States Employees: 259 Exchange: NGM

Personalis en bref

Personalis (PSNL) is currently trading at 10,98 € with a market capitalization of 1,2 Md €. The 52-week range spans from 3,33 € to 14,21 €; the current price is 22.8% below the yearly high. Year-over-year revenue growth stands at -24.9%.

💰 Dividende

Personalis currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

4 analystes évaluent Personalis (PSNL) au consensus : Acheter. L'objectif de cours moyen est de 12,03 €, soit un potentiel de +9.6% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 8,67 € à 14,09 €.

Personalis : la thèse d'investissement en détail

Personalis (PSNL) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -24.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 2.24, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Buy
  • Bilan solide avec faible endettement (D/E 15.22)
Points faibles
  • CA en contraction (-24.9% sur un an)
  • Actuellement non rentable
  • Forte volatilité (Bêta 2.24)
  • Positions vendeuses élevées (16.74%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
10,28 €
+6.75% vs. cours
MM 200 jours
7,85 €
+39.89% vs. cours
Sous le plus haut 52s
−22.8%
14,21 €
Au-dessus du plus bas 52s
+229.7%
3,33 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Risque de marché (Bêta)
2.24 · Élevé
Évolue plus que le marché global
Positions vendeuses
16.74% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
15.22 · Faible
Dette totale / capitaux propres

The data points to above-average price swings, elevated short interest (16.74%).

Trading Data

50-Day MA: 10,28 €
200-Day MA: 7,85 €
Volume: 2,744,548
Avg. Volume: 3,896,585
Short Ratio: 2.51
P/B Ratio: 5.2x
Debt/Equity: 15.22x
Free Cash Flow: -36 720 351 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Personalis?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut